MicroRNAs as lung cancer biomarkers

World Journal of Clinical Oncology

Volumn 5, Issue 4, 2014, Pages 604-620

  Del Vescovo, Valerio ^a   Grasso, Margherita ^a   Barbareschi, Mattia ^b   Denti, Michela A ^a  

^a UNIVERSITY OF TRENTO   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Biomarkers; Lung cancer; MicroRNAs; Non small cell lung carcinomas

Indexed keywords

EID: 84920273891     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i4.604     Document Type: Review

References (143)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781 [PMID: 20116997 DOI: 10.1016/j.ejca.2009.12.014]
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013; 24: 792-800 [PMID: 23402763 DOI: 10.1093/annonc/mdt010]
3. Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, Papotti M, Tironi A, Graziano P, Paci M, Stefani A, Migaldi M, Sartori G, Pelosi G. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch 2014; 464: 61-68 [PMID: 24221342 DOI: 10.1007/s00428-013-1501-6]
4. Scagliotti GV, Selvaggi G. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. Clin Lung Cancer 2008; 9 Suppl 3: S122-S128 [PMID: 19419926 DOI: 10.3816/CLC.2008.s.018]
5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597 [PMID: 15117980 DOI: 10.1200/JCO.2004.08.163]
6. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, doubleblind, phase 3 study. Lancet 2009; 374: 1432-1440 [PMID: 19767093 DOI: 10.1016/S0140-6736(09)61497-5]
7. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatinbased chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 2007; 99: 847-57 [PMID: 17551145 DOI: 10.1093/jnci/djk196]
8. Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009; 27: 1405-1412 [PMID: 19224857 DOI: 10.1200/JCO.2008.1]
9. Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, Riely GJ, Travis WD, Zakowski MF, Moreira AL. Suitability of thoracic cytology for new therapeutic paradigms in nonsmall cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451-458 [PMID: 21266922 DOI: 10.1097/JTO.0b013e31820517a]
10. Nizzoli R, Tiseo M, Gelsomino F, Bartolotti M, Majori M, Ferrari L, De Filippo M, Rindi G, Silini EM, Guazzi A, Ardizzoni A. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol 2011; 6: 489-493 [PMID: 21258246 DOI: 10.1097/JTO.0b013e31820b86cb]
11. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011; 32: 22-31 [PMID: 21500121 DOI: 10.1055/s-0031-1272866]
12. Rossi G, Pelosi G, Barbareschi M, Graziano P, Cavazza A, Papotti M. Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Int J Surg Pathol 2013; 21: 326-336 [PMID: 23740564 DOI: 10.1177/1066896913489346]
13. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci USA 2007; 104: 9667-9672 [PMID: 17535905 DOI: 10.1073/pnas.0703820104]
14. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529 [PMID: 12434020 DOI: 10.1073/pnas.242606799]
15. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833 [PMID: 15944707 DOI: 10.1038/nature03552]
16. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115 [PMID: 21125669 DOI: 10.1002/path.2806]
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838 [PMID: 15944708 DOI: 10.1038/nature03702]
18. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261 [PMID: 16461460 DOI: 10.1073/pnas.0510565103]
19. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945 DOI: 10.1038/nrc1997]
20. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462-469 [PMID: 18362881 DOI: 10.1038/nbt1392]
21. Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A, Benjamin H, Tamir R, Ezagouri M, Goren E, Barshack I, Nass D, Tobar A, Feinmesser M, Rosenfeld N, Leizerman I, Ashkenazi K, Spector Y, Chajut A, Aharonov R. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010; 23: 814-823 [PMID: 20348879 DOI: 10.1038/modpathol.2010.57]
22. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, Huszar M, Fogt F, Ashkenazi K, Sanden M, Goren E, Dromi N, Zion O, Burnstein I, Chajut A, Spector Y, Aharonov R. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012; 17: 801-812 [PMID: 22618571 DOI: 10.1634/theoncologist.2011-0466]
23. Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Goussia A, Stoyianni A, Sanden M, St Cyr B, Yerushalmi N, Benjamin H, Meiri E, Chajut A, Rosenwald S, Aharonov R, Spector Y. Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. Mol Cancer 2013; 12: 57 [PMID: 23758919 DOI: 10.1186/1476-4598-12-57]
24. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafà R, Magri E, Lunardi M, Munerato G, Querzoli G, Maestri I, Ulazzi L, Nenci I, Croce CM, Lanza G, Querzoli P, Negrini M. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011; 225: 43-53 [PMID: 21630269 DOI: 10.1002/path.2915]
25. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004 [PMID: 14973191 DOI: 10.1073/pnas.0307323101]
26. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756 [PMID: 15172979 DOI: 10.1158/0008-5472. CAN-04-0637]
27. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647 [PMID: 15766527 DOI: 10.1016/j.cell.2005.01.014]
28. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198 [PMID: 16530703 DOI: 10.1016/j.ccr.2006.01.025]
29. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y. let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer 2007; 58: 392-396 [PMID: 17728006 DOI: 10.1016/j.lungcan.2007.07.013]
30. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008; 105: 3903-3908 [PMID: 18308936 DOI: 10.1073/pnas.0712321105]
31. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68: 8535-8540 [PMID: 18922928 DOI: 10.1158/0008-5472. CAN-08-2129]
32. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA- 1 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein. (RAB14). Oncogene 2011; 30: 2644-2658 [PMID: 21358675 DOI: 10.1038/onc.2010.642]
33. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-9632 [PMID: 16266980 DOI: 10.1158/0008-5472.CAN-05-2352]
34. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T. "Targeted deletion reveals essential and overlapping functions of the miR-17~92 family of miRNA clusters.". Cell 2008; 132: 875-86 [PMID: 18329372 DOI:10.1016/j.cell.2008.02.019]
35. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494 [PMID: 2554494 DOI: 10.1126/science. 2554494]
36. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075 [PMID: 18948947 DOI: 10.1038/nature07423]
37. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134 [PMID: 17554337 DOI: 10.1038/nature05939]
38. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752 [PMID: 17540599 DOI: 10.1016/j.molcel.2007.05.010]
39. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion- independent growth. Cancer Res 2007; 67: 8433-8438 [PMID: 17823410 DOI: 10.1158/0008-5472.CAN-07-1585]
40. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-743 [PMID: 17540598 DOI: 10.1016/j.molcel.2007.05.017]
41. Jiang L, Huang Q, Chang J, Wang E, Qiu X. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res 2011; 37: 387-398 [PMID: 21777146 DOI: 10.3109/01902148.2010.492068]
42. Bisio A, De Sanctis V, Del Vescovo V, Denti MA, Jegga AG, Inga A, Ciribilli Y. Identification of new p53 target microRNAs by bioinformatics and functional analysis. BMC Cancer 2013; 13: 552 [PMID: 24256616 DOI: 10.1186/1471-2407-13-5 52]
43. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-1674 [PMID: 17698639 DOI: 10.1261/rna.642907]
44. Kim YK, Yeo J, Kim B, Ha M, Kim VN. Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell 2012; 46: 893-895 [PMID: 22749402 DOI: 10.1016/j.molcel.2012.05.036]
45. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010; 11: 31-46 [PMID: 19997069 DOI: 10.1038/nrg2626]
46. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329: 125-136 [PMID: 23196059 DOI: 10.1016/j.canlet.2012.11.001]
47. Ach RA, Wang H, Curry B. Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol 2008; 8: 69 [PMID: 18783629 DOI: 10.1186/1472-6750-8-69]
48. Chen Y, Gelfond JA, McManus LM, Shireman PK. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 2009; 10: 407 [PMID: 19715577 DOI: 10.1186/1471-2164-10-407]
49. Willenbrock H, Salomon J, Søkilde R, Barken KB, Hansen TN, Nielsen FC, Møller S, Litman T. Quantitative miRNA expression analysis: comparing microarrays with nextgeneration sequencing. RNA 2009; 15: 2028-2034 [PMID: 19745027 DOI: 10.1261/rna.1699809]
50. Sato F, Tsuchiya S, Terasawa K, Tsujimoto G. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One 2009; 4: e5540 [PMID: 19436744 DOI: 10.1371/journal.pone.0005540]
51. Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, Bertone P, Caldas C. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010; 16: 991-1006 [PMID: 20360395 DOI: 10.1261/rna.1947110]
52. Sah S, McCall MN, Eveleigh D, Wilson M, Irizarry RA. Performance evaluation of commercial miRNA expression array platforms. BMC Res Notes 2010; 3: 80 [PMID: 20298588 DOI: 10.1186/1756-0500-3-80]
53. Pradervand S, Weber J, Lemoine F, Consales F, Paillusson A, Dupasquier M, Thomas J, Richter H, Kaessmann H, Beaudoing E, Hagenbüchle O, Harshman K. Concordance among digital gene expression, microarrays, and qPCR when measuring differential expression of microRNAs. Biotechniques 2010; 48: 219-222 [PMID: 20359303 DOI: 10.2144/000113367]
54. Yauk CL, Rowan-Carroll A, Stead JD, Williams A. Crossplatform analysis of global microRNA expression technologies. BMC Genomics 2010; 11: 330 [PMID: 20504329 DOI: 10.1186/1471-2164-11-330]
55. Wang B, Howel P, Bruheim S, Ju J, Owen LB, Fodstad O, Xi Y. Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array. PLoS One 2011; 6: e17167 [PMID: 21347261 DOI: 10.1371/journal.pone.0017167]
56. Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM, Pierotti MA, Daidone MG, Canevari S, De Cecco L. Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS One 2012; 7: e45105 [PMID: 23028787 DOI: 10.1371/journal.pone.0045105]
57. Leshkowitz D, Horn-Saban S, Parmet Y, Feldmesser E. Differences in microRNA detection levels are technology and sequence dependent. RNA 2013; 19: 527-538 [PMID: 23431331 DOI: 10.1261/rna.036475.112]
58. Kolbert CP, Feddersen RM, Rakhshan F, Grill DE, Simon G, Middha S, Jang JS, Simon V, Schultz DA, Zschunke M, Lingle W, Carr JM, Thompson EA, Oberg AL, Eckloff BW, Wieben ED, Li P, Yang P, Jen J. Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues. PLoS One 2013; 8: e52517 [PMID: 23382819 DOI: 10.1371/journal.pone.0052517]
59. Del Vescovo V, Meier T, Inga A, Denti MA, Borlak J. A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice. PLoS One 2013; 8: e78870 [PMID: 24265725 DOI: 10.1371/journal.pone.0078870]
60. Benes V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 2010; 50: 244-249 [PMID: 20109550 DOI: 10.1016/j.ymeth.2010.01.026]
61. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27: 1859-1867 [PMID: 17194750 DOI: 10.1128/MCB.01395-06]
62. Nadano D, Sato TA. Caspase-3-dependent and -independent degradation of 28 S ribosomal RNA may be involved in the inhibition of protein synthesis during apoptosis initiated by death receptor engagement. J Biol Chem 2000; 275: 13967-13973 [PMID: 10788523 DOI: 10.1074/jbc.275.18.13967]
63. Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, Liyanarachchi S, Brown R, Nephew KP, Yan PS, Huang TH. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 2005; 11: 7376-7383 [PMID: 16243810 DOI: 10.1158/1078-0432.CCR-05-1100]
64. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70: 36-45 [PMID: 20028859 DOI: 10.1158/0008-5472.CAN-09-3153]
65. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008; 14: 844-852 [PMID: 18375788 DOI: 10.1261/rna.939908]
66. Schaefer A, Jung M, Miller K, Lein M, Kristiansen G, Erbersdobler A, Jung K. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 2010; 42: 749-758 [PMID: 20890088 DOI: 10.3858/emm.2010.42.11.076]
67. Wotschofsky Z, Meyer HA, Jung M, Fendler A, Wagner I, Stephan C, Busch J, Erbersdobler A, Disch AC, Mollenkopf HJ, Jung K. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem 2011; 417: 233-241 [PMID: 21741950 DOI: 10.1016/j.ab.2011.06.009]
68. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011; 104: 1168-1177 [PMID: 21407217 DOI: 10.1038/sj.bjc.6606076]
69. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 2013; 10: 1003-1005 [PMID: 23995387 DOI: 10.1038/nmeth.2633]
70. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009; 4: e6677 [PMID: 19688090 DOI: 10.1371/journal. pone.0006677]
71. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, Mc- Shane LM, Wang E. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010; 16: 430-441 [PMID: 20068076 DOI: 10.1158/1078-0432. CCR-09-1736]
72. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009; 69: 5776-5783 [PMID: 19584273]
73. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011; 17: 6802-6811 [PMID: 21890451]
74. Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, Cohen L, Dan H, Zion O, Strenov Y, Polak-Charcon S, Perelman M. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 2010; 206: 578-584 [PMID: 20418022 DOI: 10.1016/j.prp.2010.03.005]
75. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. Diagnostic assay based on hsamiR-1 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009; 27: 2030-2037 [PMID: 19273703 DOI: 10.1200/JCO.2008.19.4134]
76. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010; 16: 610-619 [PMID: 20068099 DOI: 10.1158/1078-0432.CCR-09-2638.]
77. Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, Fasanella S, Cuorvo LV, Palma PD, Rossi G, Papotti M, Pelosi G, Graziano P, Cavazza A, Denti MA, Barbareschi M. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 2011; 35: 268-275 [PMID: 21263248 DOI: 10.1097/PAS.0b013e3182068171]
78. Barbareschi M, Cantaloni C, Del Vescovo V, Cavazza A, Monica V, Carella R, Rossi G, Morelli L, Cucino A, Silvestri M, Tirone G, Pelosi G, Graziano P, Papotti M, Dalla Palma P, Doglioni C, Denti MA. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNAbased analysis. Am J Clin Pathol 2011; 136: 773-782 [PMID: 22031317 DOI: 10.1309/AJCPYY79XAGRAYCJ]
79. Lee HW, Lee EH, Ha SY, Lee CH, Chang HK, Chang S, Kwon KY, Hwang IS, Roh MS, Seo JW. Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. Pathol Int 2012; 62: 583-591 [PMID: 22924844 DOI: 10.1111/j.1440-1827.2012.02845.x]
80. Huang W, Hu J, Yang DW, Fan XT, Jin Y, Hou YY, Wang JP, Yuan YF, Tan YS, Zhu XZ, Bai CX, Wu Y, Zhu HG, Lu SH. Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. Am J Respir Crit Care Med 2012; 186: 1160-1167 [PMID: 23043084 DOI: 10.1164/rccm.201203-0534OC]
81. Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, Bibbo M, Thurm C, Horowitz L, Huang Y, Feinmesser M, Hou JS, St Cyr B, Burnstein I, Gibori H, Dromi N, Sanden M, Kushnir M, Aharonov R. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn 2012; 14: 510-517 [PMID: 22749746 DOI: 10.1016/j.jmoldx.2012.03.004]
82. Petriella D, Galetta D, Rubini V, Savino E, Paradiso A, Simone G, Tommasi S. Molecular profiling of thin-prep FNA samples in assisting clinical management of non-smallcell lung cancer. Mol Biotechnol 2013; 54: 913-919 [PMID: 23277327 DOI: 10.1007/s12033-012-9640-6]
83. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008; 13: 48-57 [PMID: 18167339 DOI: 10.1016/j.ccr.2007.12.008]
84. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009; 30: 1903-1909 [PMID: 19736307 DOI: 10.1093/carcin/bgp219]
85. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One 2012; 7: e46045 [PMID: 23029380 DOI: 10.1371/journal.pone.0046045]
86. Navarro A, Diaz T, Gallardo E, Viñolas N, Marrades RM, Gel B, Campayo M, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol 2011; 103: 411-415 [PMID: 21400525 DOI: 10.1002/jso.21847]
87. Campayo M, Navarro A, Viñolas N, Diaz T, Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M, Marrades R. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J 2013; 41: 1172-1178 [PMID: 22835608 DOI: 10.1183/09031936.00048712]
88. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010; 64: 399-408 [PMID: 20363096 DOI: 10.1016/j.biopha.2010.01.018]
89. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S, Weiss GJ. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 2011; 129: 2621-2631 [PMID: 21448905 DOI: 10.1002/ijc.2]
90. Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012; 13: 330-340 [PMID: 22237007 DOI: 10.4161/cbt.19073]
91. Zhan X, Wu W, Han B, Gao G, Qiao R, Lv J, Zhang S, Zhang W, Fan W, Chen H, Zhang T, Gu A, Shen J, Wu Q, Lu D. Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population. J Clin Lab Anal 2012; 26: 441-446 [PMID: 23143626 DOI: 10.1002/jcla.21544]
92. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008; 19: 1053-1059 [PMID: 18304967 DOI: 10.1093/annonc/mdn006]
93. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012; 18: 74-82 [PMID: 22157681 DOI: 10.1038/nm.2577]
94. Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang F, Zhang SC. miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chin Med J (Engl) 2013; 126: 4435-4439 [PMID: 24286402 DOI: 10.3760/cma.j.issn.0366-6999.20131112]
95. Hubers AJ, Prinsen CF, Sozzi G, Witte BI, Thunnissen E. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer 2013; 109: 530-537 [PMID: 23868001 DOI: 10.1038/bjc.2013.393]
96. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010; 67: 170-176 [PMID: 19446359 DOI: 10.1016/j.lungcan.2009.04.004]
97. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010; 23: 1157-1164 [PMID: 20526284 DOI: 10.1038/modpathol.2010.111]
98. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL, Jiang F. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010; 127: 2870-2878 [PMID: 21351266 DOI: 10.1002/ijc.25289]
99. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol 2014; 140: 145-150 [PMID: 24281335 DOI: 10.1007/s00432-013-1555-5]
100. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, Jiang F. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol 2014; 9: 33-40 [PMID: 24305007 DOI: 10.1097/JTO.0000000000000025]
101. Roa WH, Kim JO, Razzak R, Du H, Guo L, Singh R, Gazala S, Ghosh S, Wong E, Joy AA, Xing JZ, Bedard EL. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med 2012; 35: E271 [PMID: 23043708]
102. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour- associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675 [PMID: 18318758 DOI: 10.1111/j.1365-2141.2008.07077.x]
103. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518 [PMID: 18663219 DOI: 10.1073/pnas.0804549105]
104. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3: e3148 [PMID: 18773077 DOI: 10.1371/journal.pone.0003148]
105. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741 [PMID: 20847327 DOI: 10.1373/clinchem.2010.147405]
106. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32: 326-348 [PMID: 22383180 DOI: 10.1002/med.20215]
107. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-579 [PMID: 12154376 DOI: 10.1038/nri855]
108. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009; 6: 267-283 [PMID: 19489699 DOI: 10.1586/epr.09.17]
109. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006; 48: 180-186 [PMID: 16801490 DOI: 10.1161/01.HYP.0000231507.00962.b5]
110. Beyer C, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 2010; 6: 21-29 [PMID: 19949432 DOI: 10.1038/nrrheum.2009.229]
111. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659 [PMID: 17486113 DOI: 10.1038/ncb1596]
112. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694 [PMID: 19002258 DOI: 10.1371/journal.pone.0003694]
113. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81 [PMID: 19996457 DOI: 10.1126/scisignal.2000610]
114. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012; 93: 555-562 [PMID: 22028337 DOI: 10.1093/cvr/cvr266]
115. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009; 11: 1143-1149 [PMID: 19684575 DOI: 10.1038/ncb1929]
116. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008 [PMID: 21383194 DOI: 10.1073/pnas.1019055108]
117. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-7233 [PMID: 21609964 DOI: 10.1093/nar/gkr254]
118. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010; 38: 7248-7259 [PMID: 20615901 DOI: 10.1093/nar/gkq601]
119. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-433 [PMID: 21423178 DOI: 10.1038/ncb2210]
120. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]
121. Zhu X, Li H, Long L, Hui L, Chen H, Wang X, Shen H, Xu W. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 519-526 [PMID: 22510476 DOI: 10.1093/abbs/gms026]
122. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 2012; 57: 897-904 [PMID: 22198701 DOI: 10.1007/s10620-011-1981-7]
123. Sanders I, Holdenrieder S, Walgenbach-Brünagel G, von Ruecker A, Kristiansen G, Müller SC, Ellinger J. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol 2012; 19: 1017-1025 [PMID: 22788411 DOI: 10.1111/j.1442-2042.2012.03082.x]
124. Appaiah HN, Goswami CP, Mina LA, Badve S, Sledge GW, Liu Y, Nakshatri H. Persistent upregulation of U6: SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res 2011; 13: R86 [PMID: 21914171 DOI: 10.1186/bcr2943]
125. Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn 2013; 15: 827-834 [PMID: 23988620 DOI: 10.1016/j.jmoldx.2013.07.005]
126. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011; 4: 575-586 [PMID: 21904633]
127. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011; 91: 579-587 [PMID: 21116241 DOI: 10.1038/labinvest.2010.194]
128. Ma J, Li N, Guarnera M, Jiang F. Quantification of Plasma miRNAs by Digital PCR for Cancer Diagnosis. Biomark Insights 2013; 8: 127-136 [PMID: 24277982 DOI: 10.4137/BMI. S13154]
129. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev 2013; 22: 540-548 [PMID: 23462458 DOI: 10.1097/CEJ.0b013e32835f3be9]
130. Roth C, Stuckrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating miR- 361-3p and miR-625∗as blood-based markers for discriminating malignant from benign lung tumors. PloS One 2012; 7: e38248 [PMID: 22675530 DOI: 10.1371/journal. pone.0038248]
131. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012; 130: 1378-1386 [PMID: 21544802 DOI: 10.1002/ijc.26153]
132. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011; 3: 495-503 [PMID: 21744498 DOI: 10.1002/emmm.201100154]
133. Jiang M, Zhang P, Hu G, Xiao Z, Xu F, Zhong T, Huang F, Kuang H, Zhang W. Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem 2013; 383: 67-75 [PMID: 23881177 DOI: 10.1007/s11010-013-1755-y]
134. Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, Russo A, Giordano A, Adamo V. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced nonsmall cell lung cancer. J Cell Physiol 2014; 229: 97-99 [PMID: 23794259 DOI: 10.1002/jcp.24422]
135. Aushev VN, Zborovskaya IB, Laktionov KK, Girard N, Cros MP, Herceg Z, Krutovskikh V. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One 2013; 8: e78649 [PMID: 24130905 DOI: 10.1371/journal. pone.0078649]
136. Keller A, Backes C, Leidinger P, Kefer N, Boisguerin V, Barbacioru C, Vogel B, Matzas M, Huwer H, Katus HA, Stähler C, Meder B, Meese E. Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol Biosyst 2011; 7: 3187-3199 [PMID: 22027949 DOI: 10.1039/c1mb05353a]
137. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011; 108: 3713-3718 [PMID: 21300873 DOI: 10.1073/pnas.1100048108]
138. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, Marchiano A, Negri E, La Vecchia C, Pastorino U. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014; 32: 768-773 [PMID: 24419137]
139. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28: 1721-1726 [PMID: 20194856 DOI: 10.1200/JCO.2009.24.9342]
140. Silva J, García V, Zaballos Á, Provencio M, Lombardía L, Almonacid L, García JM, Domínguez G, Peña C, Diaz R, Herrera M, Varela A, Bonilla F. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011; 37: 617-623 [PMID: 20595154 DOI: 10.1183/09031936.00029610]
141. Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 2012; 138: 2045-2050 [PMID: 22806310 DOI: 10.1007/s00432-012-1285-0]
142. Shen Y, Tang D, Yao R, Wang M, Wang Y, Yao Y, Li X, Zhang H. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol 2013; 30: 750 [PMID: 24198203 DOI: 10.1007/s12032-013-0750-1]
143. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18: 1121-1126 [PMID: 21633392 DOI: 10.1038/gt.2011.79]